Filtros de búsqueda

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study

scientific article published on 26 June 2019

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.

artículo científico publicado en 2016

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer ⬇️

artículo científico publicado el 1 de noviembre de 2011

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

artículo científico publicado en 2015

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

artículo científico publicado en 2002

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer

artículo científico publicado en 2003

A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer

artículo científico publicado en 2006

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

scientific article published on 24 December 2019

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

artículo científico publicado en 2019

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce

artículo científico publicado en 2019

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Canc

scientific article published on 09 October 2019

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

artículo científico publicado en 2010

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

artículo científico publicado en 2007

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

artículo científico publicado en 2008

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

artículo científico publicado en 2005

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer

artículo científico publicado en 2002

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies

artículo científico publicado en 2006

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

artículo científico publicado en 2005

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2016

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

scientific article published on 24 April 2020

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors

scientific article published on 31 August 2018

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

artículo científico publicado en 2014

A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors

artículo científico publicado en 2018

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

artículo científico publicado en 2003

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

artículo científico publicado en 2013

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

artículo científico publicado en 2005

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

artículo científico publicado en 2005

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

artículo científico publicado en 2006

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

artículo científico publicado en 2013

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321

artículo científico publicado en 2015

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced

artículo científico publicado en 2017

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

artículo científico publicado en 2005

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

artículo científico publicado en 2005

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

artículo científico publicado en 2019

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

artículo científico publicado en 2014

A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials

artículo científico publicado en 2006

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528

artículo científico publicado en 2013

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation

artículo científico publicado en 2007

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

scientific article published on 24 December 2008

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

artículo científico publicado en 2017

Advances in chemotherapy of non-small cell lung cancer

artículo científico publicado en 2006

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

artículo científico publicado en 2008

Analysis of second primary lung cancers in the SEER database

artículo científico publicado en 2010

Angiogenesis inhibitors in lung cancer: a promise fulfilled

artículo científico publicado en 2006

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

artículo científico publicado en 2016

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

scientific article published on 30 December 2018

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer

artículo científico

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

artículo científico publicado en 2008

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations

scientific article published on 04 September 2018

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

artículo científico publicado en 2012

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

artículo científico publicado en 2018

Cancer symposium for the practitioner: introduction to solid tumors

artículo científico publicado en 2007

Cardiovascular safety and population pharmacokinetic properties of piperaquine in African patients with uncomplicated falciparum malaria - a pooled multicentre analysis

artículo científico publicado en 2020

Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer

artículo científico publicado en 2014

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

artículo científico publicado en 2018

Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarb

artículo científico publicado en 2005

Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003

artículo científico publicado en 2005

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors

artículo científico publicado en 2002

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials

artículo científico publicado en 2011

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials

artículo científico publicado en 2004

Consensus report of the 2015 Weinman International Conference on Mesothelioma

artículo científico publicado en 2016

Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?

artículo científico publicado en 2008

Cooperative group research endeavors in small-cell lung cancer: current and future directions

artículo científico publicado en 2009

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

artículo científico publicado en 2010

Current Diagnosis and Management of Small-Cell Lung Cancer

artículo científico publicado en 2019

Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundatio

artículo científico publicado en 2018

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

artículo científico publicado en 2006

Dehydroepiandrosterone for the treatment of hot flashes: a pilot study

artículo científico publicado en 2006

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2018

Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?

artículo científico publicado en 2020

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

artículo científico publicado en 2011

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

artículo científico publicado en 2011

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways

artículo científico publicado en 2016

Emerging therapeutic targets in non-small cell lung cancer

artículo científico publicado en 2009

Endpoints in phase II trials for advanced non-small cell lung cancer

artículo científico publicado en 2010

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012

artículo científico publicado en 2016

Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study

artículo científico publicado en 2009

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data

artículo científico publicado en 2008

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

artículo científico

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

artículo científico publicado en 2004

Farnesyltransferase inhibitors in breast cancer therapy

artículo científico publicado en 2002

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

artículo científico publicado en 2017

Guidelines for Statistical Reporting in Medical Journals

artículo científico publicado en 2020

Human aromatase: gene resequencing and functional genomics

artículo científico publicado en 2005

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

scientific article published on 01 September 2007

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

artículo científico publicado en 2012

Impact of disease progression date determination on progression‐free survival estimates in advanced lung cancer ⬇️

artículo científico publicado el 20 de marzo de 2012

Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials

artículo científico publicado en 2006

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de junio de 2011

Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer

artículo científico publicado en 2019

Introducing the Journal of Thoracic Oncology Statistical Series

artículo científico publicado en 2020

Introduction to a cancer symposium for the practitioner

scientific article published on 01 August 2005

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

artículo científico publicado en 2003

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).

artículo científico publicado en 2017

Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non–Small-Cell Lung Cancer: A Case-Based Review ⬇️

artículo científico publicado el 28 de abril de 2011

Management of Multifocal Lung Cancer: Results of a Survey

artículo científico publicado en 2017

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

artículo científico publicado en 2007

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells

artículo científico publicado en 2008

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

artículo científico publicado en 2008

Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms

artículo científico publicado en 2016

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer ⬇️

artículo científico publicado el 22 de febrero de 2013

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status

artículo científico publicado en 2014

Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches

artículo científico publicado en 2020

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

artículo científico publicado en 2008

North Central Cancer Treatment Group--achievements and perspectives

artículo científico publicado en 2008

Novel targets for lung cancer therapy: part I.

artículo científico publicado en 2002

Novel targets for lung cancer therapy: part II.

artículo científico publicado en 2002

Obstacles and opportunities in the clinical development of targeted therapeutics.

artículo científico publicado en 2005

Outstanding Issues with Umbrella and Basket Studies

artículo científico publicado en 2019

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

scientific article published on 28 June 2019

Pathophysiology and treatment of hot flashes

artículo científico publicado en 2002

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

scientific article published on 26 July 2013

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

artículo científico publicado en 2005

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

artículo científico publicado en 2014

Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors

artículo científico publicado en 2015

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer ⬇️

artículo científico publicado el 14 de febrero de 2012

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

artículo científico publicado en 2005

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors

artículo científico publicado en 2003

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

artículo científico publicado en 2005

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

artículo científico publicado en 2013

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

artículo científico publicado en 2007

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

artículo científico publicado en 2000

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

artículo científico publicado en 2008

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

artículo científico publicado en 2014

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

artículo científico publicado en 2005

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

scientific article published on 01 March 1999

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer

scientific article published on 01 May 2007

Phase II Evaluation of Desipramine for the Treatment of Hot Flashes

artículo científico publicado en 2007

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer

artículo científico publicado en 2014

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2003

Phase II trial of KW2189 in patients with advanced malignant melanoma

artículo científico publicado en 2002

Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.

artículo científico publicado en 2010

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

artículo científico publicado en 2009

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

artículo científico publicado en 2007

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib ⬇️

artículo científico publicado el 8 de noviembre de 2012

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors ⬇️

artículo científico publicado el 22 de noviembre de 2012

Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine

artículo científico publicado en 2005

Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana

artículo científico publicado en 2017

Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer

artículo científico publicado en 2009

Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials

artículo científico publicado en 2009

Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania

artículo científico publicado en 2015

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

artículo científico publicado en 2017

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesoth

artículo científico publicado en 2019

Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution

artículo científico publicado en 2005

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

artículo científico publicado en 2005

Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma

scientific article published on 01 May 2020

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years

artículo científico publicado en 2017

Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer

artículo científico publicado en 2006

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).

artículo científico publicado en 2007

Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly.

artículo científico publicado en 2005

SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma

artículo científico publicado en 2006

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

artículo científico publicado en 2019

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

artículo científico publicado en 2005

Small Cell Lung Cancer

scientific article published on 01 March 2008

Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.

artículo científico publicado en 2011

Strategies for improving outcomes in NSCLC: a look to the future

artículo científico

Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors

artículo científico publicado en 2010

Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

artículo científico publicado en 2008

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents

artículo científico publicado en 2006

Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers

artículo científico publicado en 2018

Systemic cancer therapy: evolution over the last 60 years

artículo científico publicado en 2008

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

artículo científico

Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination

scientific article published on 14 July 2020

The Ras/Raf/MAPK pathway

artículo científico publicado en 2006

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Appl

artículo científico publicado en 2019

The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation

artículo científico publicado en 2010

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

artículo científico publicado en 2005

The role of farnesyltransferase inhibitors in lung cancer therapy

artículo científico publicado en 2002

The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer

artículo científico publicado en 2007

Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).

artículo científico publicado en 2009

Treatment guidance for lung cancer patients during the COVID-19 pandemic

scientific article published on 13 May 2020

Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens

scientific article published on 05 February 2020

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials

artículo científico publicado en 2010

Understanding, recognizing, and managing toxicities of targeted anticancer therapies ⬇️

artículo científico publicado el 28 de mayo de 2013

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

artículo científico publicado en 2017

Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients

scientific article published on 17 September 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda